Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

About the Cover

May 2009; Volume 50,Issue 5

Cover image

Cover image expansion

The biodistribution and dosimetry of 18F-flutemetamol, a newly developed radioligand to visualize and quantify amyloid burden, have been characterized. Here, PET slices through the brain of a healthy subject (top) and a patient with Alzheimer disease (bottom) show the distribution of uptake. Specific uptake is present in gray matter in patients, and aspecific uptake is seen in white matter, pons, and thalamus. Variability in dosimetry between subjects was relatively low.
See page 818.

Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 50 (5)
Journal of Nuclear Medicine
Vol. 50, Issue 5
May 2009
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Supplemental Data
  • Supplemental Data
  • Supplemental Data
  • Supplemental Data
  • Supplemental Data
  • Supplemental Data
Sign up for alerts

Jump to

  • This Month in JNM
  • SNM Newsline
  • Focus on Molecular Imaging
  • Invited Perspectives
  • Clinical Investigations
  • Continuing Education
  • Basic Science Investigations
  • Letters to the Editor
  • Book Reviews
  • Most Cited
  • Most Read
Loading
  • Performance Evaluation of the uEXPLORER Total-Body PET/CT Scanner Based on NEMA NU 2-2018 with Additional Tests to Characterize PET Scanners with a Long Axial Field of View
  • Slow but Evident Recovery from Neocortical Dysfunction and Cognitive Impairment in a Series of Chronic COVID-19 Patients
  • Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas
  • Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns
  • Molecular Imaging Findings on Acute and Long-Term Effects of COVID-19 on the Brain: A Systematic Review
More...
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire